Home » News » Clinical Intelligence » Cara Therapeutics initiates phase II CR845 trial

Cara Therapeutics initiates phase II CR845 trial

Wednesday, August 3, 2011

Cara Therapeutics has begun the dosing of the first patient in a phase II clinical trial of its peripherally-selective, kappa opioid agonist, CR845, for the treatment of acute post-operative pain. The double-blind, placebo-controlled trial is expected to enroll a minimum of 200 patients at multiple clinical sites in the United States, and will evaluate the efficacy and safety of intravenous CR845 administered both pre- and post-operatively in women undergoing laparoscopic hysterectomy. This trial follows the successful completion of a 46 patient, multi-center, double-blind phase II study of CR845, in the same surgical population, where both analgesic and opioid-sparing effects of CR845 were demonstrated and the drug was found to be safe and well tolerated after a single post-operative dose.

“This trial is of particular importance as it will reinforce previous positive phase II results for CR845 in a single-dose postoperative pain study,” said Timothy Melson, M.D., study principal investigator, anesthesiologist and pain management specialist, at Helen Keller Memorial Hospital in Sheffield, AL.  

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!